Results 221 to 230 of about 212,546 (262)
Some of the next articles are maybe not open access.
Immunotherapy for Acute Myeloid Leukemia
Seminars in Hematology, 2015Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S. +3 more
openaire +3 more sources
Metabolomics in acute myeloid leukemia
Molecular Genetics and Metabolism, 2020Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML.
Anna V, Wojcicki +3 more
openaire +2 more sources
Current Opinion in Oncology, 1992
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +3 more sources
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +3 more sources
Current Opinion in Hematology, 1997
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
JAMA
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
Vindesine effect in myeloid leukemia
Cancer Chemotherapy and Pharmacology, 1982Vindesine (VDS), a semisynthetic vinca alkaloid derivative, was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy to seven patients with chronic myeloid leukemia (CML), 17 patients with chronic myeloid leukemia in blastic metamorphosis (CML/BM), and 12 patients with acute nonlymphocytic leukemia (ANLL).
M, Baccarani +3 more
openaire +2 more sources
Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology, 2001Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel +3 more
openaire +2 more sources
Chronic myeloid leukemia transformation into acute myeloid leukemia
Indonesian Journal of Biomedicine and Clinical SciencesChronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by excessive accumulation of apparently normal myeloid cells and the Philadelphia chromosome resulting from t(9;22) reciprocal chromosomal translocation and leading to BCR-ABL fusion gene formation.
null Nugra Akzatama +1 more
openaire +1 more source
Acute myeloid leukemia in adults
Current Treatment Options in Oncology, 2000The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire +2 more sources
Transplantation in Acute Myeloid Leukemia
Hematology/Oncology Clinics of North America, 2014Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire +2 more sources